Skip to main content
. 2019 Jul 29;179(10):1388–1397. doi: 10.1001/jamainternmed.2019.2407

Table 3. SAQ Measurements During the Entire Study.

Outcome Measure DAM (n = 99) NAM (n = 99) SA (n = 101) WL (n = 99) P Value Value of Pairwise Comparison
DAM vs NAM DAM vs SA DAM vs WL
Effect Size (95% CI) P Valuea Effect Size (95% CI) P Valuea Effect Size (95% CI) P Valuea
Physical limitation score, mean (SD)
Baseline 54.21 (13.89) 55.33 (13.51) 54.63 (12.69) 54.64 (12.45) .95 NA NA NA NA NA NA
Treatment for 1-4 wk 58.41 (12.29) 58.44 (10.87) 56.54 (12.11) 55.37 (11.58) .20 NA NA NA NA NA NA
After treatment, wk
5-8 60.58 (9.79) 59.31 (9.73) 57.26 (11.50) 56.17 (11.04) .02 0.13 (−0.15 to 0.41) .41 0.31 (0.03 to 0.59) .03 0.42 (0.14 to 0.70) .005
9-12 60.54 (9.60) 58.71 (9.95) 57.07 (11.54) 56.95 (11.11) .07 NA NA NA NA NA NA
13-16 62.07 (10.11) 59.20 (9.60) 57.37 (11.68) 55.68 (10.61) <.001 0.29 (0.01 to 0.57) .07 0.43 (0.15 to 0.71) .002 0.62 (0.33 to 0.90) <.001
Angina stability score, mean (SD)
Baseline 48.48 (17.06) 48.48 (19.17) 49.01 (18.00) 46.72 (16.62) .81 NA NA NA NA NA NA
Treatment for 1-4 wk 86.96 (15.50) 73.67 (23.00) 64.90 (24.98) 54.26 (22.49) <.001 0.68 (0.39 to 0.96) <.001 1.06 (0.76 to 1.35) <.001 1.69 (1.36 to 2.01) <.001
After treatment, wk
5-8 72.55 (24.88) 60.75 (26.94) 60.97 (23.56) 56.38 (20.72) <.001 0.46 (0.17 to 0.74) .001 0.48 (0.19 to 0.76) <.001 0.71 (0.42 to 0.99) <.001
9-12 69.44 (23.64) 53.49 (24.34) 56.89 (22.07) 58.24 (22.42) <.001 0.66 (0.38 to 0.95) <.001 0.55 (0.26 to 0.83) <.001 0.49 (0.20 to 0.77) .001
13-16 70.83 (23.18) 55.98 (21.41) 52.58 (22.39) 53.23 (20.27) <.001 0.67 (0.38 to 0.95) <.001 0.80 (0.51 to 1.09) <.001 0.81 (0.52 to 1.09) <.001
Angina frequency score, mean (SD)
Baseline 68.89 (9.99) 67.47 (11.72) 69.21 (11.20) 67.68 (11.50) .61 NA NA NA NA NA NA
Treatment for 1-4 wk 77.61 (8.82) 74.36 (8.87) 72.32 (10.77) 69.26 (11.85) <.001 0.37 (0.09 to 0.65) .03 0.54 (0.25 to 0.82) <.001 0.80 (0.51 to 1.09) <.001
After treatment, wk
5-8 80.54 (9.99) 75.59 (10.47) 73.78 (10.80) 69.79 (12.27) <.001 0.48 (0.20 to 0.76) .002 0.65 (0.36 to 0.93) <.001 0.96 (0.66 to 1.25) <.001
9-12 83.00 (10.43) 75.27 (9.04) 74.49 (11.04) 70.96 (11.46) <.001 0.79 (0.50 to 1.08) <.001 0.79 (0.50 to 1.08) <.001 1.10 (0.80 to 1.39) <.001
13-16 84.11 (11.01) 75.76 (10.40) 75.36 (11.19) 70.97 (12.25) <.001 0.78 (0.49 to 1.07) <.001 0.79 (0.50 to 1.07) <.001 1.13 (0.82 to 1.42) <.001
Treatment satisfaction score, mean (SD)
Baseline 57.87 (18.04) 60.78 (15.99) 59.70 (15.99) 58.88 (16.73) 0.66 NA NA NA NA NA NA
Treatment for 1-4 wk 72.25 (12.47) 69.15 (13.69) 66.07 (13.34) 59.26 (15.77) <.001 0.24 (–0.04 to 0.52) .13 0.48 (0.20 to 0.76) .002 0.91 (0.62 to 1.20) <.001
After treatment, wk
5-8 73.08 (12.70) 67.49 (13.03) 65.55 (12.56) 61.33 (12.95) <.001 0.43 (0.15 to 0.71) .003 0.60 (0.31 to 0.88) <.001 0.92 (0.62 to 1.21) <.001
9-12 72.94 (11.89) 67.68 (12.22) 65.73 (12.56) 63.45 (11.92) <.001 0.44 (0.15 to 0.72) .004 0.59 (0.30 to 0.87) <.001 0.80 (0.50 to 1.08) <.001
13-16 74.44 (12.54) 66.62 (12.61) 65.68 (13.23) 63.19 (13.77) <.001 0.62 (0.33 to 0.90) <.001 0.68 (0.39 to 0.96) <.001 0.85 (0.56 to 1.14) <.001
QoL score, mean (SD)
Baseline 42.42 (17.86) 43.60 (18.09) 41.75 (15.92) 43.10 (14.87) .87 NA NA NA NA NA NA
Treatment for 1-4 wk 50.45 (17.00) 47.43 (18.00) 45.45 (15.26) 46.45 (16.28) .19 NA NA NA NA NA NA
After treatment, wk
5-8 51.90 (16.16) 47.31 (17.38) 46.34 (15.51) 46.28 (15.73) .06 NA NA NA NA NA NA
9-12 51.20 (16.12) 48.39 (16.68) 47.19 (15.69) 48.14 (15.22) .36 NA NA NA NA NA NA
13-16 52.59 (15.18) 47.83 (16.66) 48.20 (16.15) 48.21 (14.00) .12 NA NA NA NA NA NA

Abbreviations: DAM, disease-affected meridian; NA, not applicable; NAM, nonaffected meridian; QoL, quality of life; SA, sham acupuncture; SAQ, Seattle Angina Questionnaire; WL, wait list.

a

Based on the Bonferroni adjustment in pairwise comparison and on analysis of variance.